Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...
Ideaya Biosciences, Inc.'s stock faces pressure from macroeconomic shifts and FDA policies, but remains a buy for savvy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback